Development of immunotherapy against regulatory T cells targeting a new biomarker, VEGFR2

针对新生物标志物 VEGFR2 的调节性 T 细胞免疫疗法的开发

• 批准号: 23591894
• 负责人: ONISHI Hideya
• 金额: $ 3.41万
• 依托单位: Kyushu University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23591894/
• 关键词: 制御性T細胞; VEGFR2; FOXP3; 細胞障害性T細胞; 抗腫瘍効果; 制御性Ｔ細胞; 細胞障害性Ｔ細胞; 大腸がん; 予後予測因子; VEGF

Relation between the number of tumor-infiltrated VEGFR2+ regulatory T (Treg) cells and prognosis in colorectal cancer patients with curative surgical resection was analyzed. The number of tumor-infiltrated VEGFR2+FOXP3+Treg cells was an independent prognostic factor for colorectal cancer. These results indicate the validity that VEGFR2+ Treg could be a therapeutic target. In vitro experiment, protein-bound polysaccharide, basiliximab, Cox-2 inhibitor and bevacizumab significantly reduced Treg number. Activate T lymphocytes induced after the depletion of Treg using basiliximab showed the increase of cytotoxicity against cancer cells.

分析结直肠癌根治性手术切除患者肿瘤浸润VEGFR2+调节性T （Treg）细胞数量与预后的关系。肿瘤浸润的VEGFR2+FOXP3+Treg细胞数量是结直肠癌的独立预后因素。这些结果表明VEGFR2+ Treg可能是一个有效的治疗靶点。体外实验中，蛋白结合多糖、巴昔单抗、Cox-2抑制剂和贝伐单抗均可显著降低Treg数量。使用basiliximab消耗Treg后诱导的活化T淋巴细胞显示对癌细胞的细胞毒性增加。

项目成果

九州大学大学院医学研究院 腫瘍制御学分野 ホームページ

九州大学医学研究科肿瘤防治科主页